Dr. Diaz is a distinguished physician-scientist who leads the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. Prior to moving to New York, he was a faculty member at the Johns Hopkins University School of Medicine. Over the years, his teams provided the first definitive evidence for using circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease. His team was also discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors. This research led to the historic first pan-tumor FDA approval for any solid tumors with this genetic lesion and the first cancer study that resulted in a 100% complete response rate. He is the recipient of numerous recognitions for his work including the Waun Ki Hong Award for Outstanding Achievement in Cancer Research. He was also the leader of the SU2C Colon Cancer Dream Team, Editor-in-Chief of Cancer Discovery and is an elected member of the Giants of Cancer Care, the AACR Fellows Academy, the American Society of Clinical Investigation, and the American Academy of Physicians. In 2021, Dr. Diaz was appointed by President Joseph Biden to the National Cancer Advisory Board.